Roche / Genentech pipeline at a glance (June 2026)
About the Roche / Genentech clinical program
Roche and its US subsidiary Genentech operate one of the deepest oncology and immunology pipelines in the industry. Their PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) anchors a broad combination program across solid tumors. In hematology, obinutuzumab, polatuzumab vedotin, and CD20xCD3 bispecific antibodies (mosunetuzumab, glofitamab) represent a comprehensive B-cell malignancy platform. In neuroscience, Ocrevus (ocrelizumab) for multiple sclerosis and the Alzheimer's pipeline (gantenerumab follow-ons) drive significant clinical activity. Roche's bispecific antibody platform is among the industry's most prolific — generating multiple new trials annually.
Key therapeutic areas
- Oncology (hematology, solid tumors)
- Neuroscience (MS, Alzheimer's)
- Immunology / ophthalmology
- Bispecific antibodies
- Blood cancers / lymphoma
Key pipeline programs
- Tecentriq (atezolizumab) — PD-L1 checkpoint inhibitor
- Ocrevus (ocrelizumab) — multiple sclerosis
- Polivy (polatuzumab vedotin) — DLBCL ADC
- Lunsumio (mosunetuzumab) — CD20xCD3 bispecific
- Columvi (glofitamab) — CD20xCD3 bispecific
- Faricimab — bispecific ophthalmology (AMD, DME)
Monitor the Roche / Genentech pipeline daily
Get alerts when Roche / Genentech registers new trials or updates existing protocols. Free plan — no credit card required.
Start Monitoring FreeTop Roche / Genentech trial indications
| Condition / Indication | Trials |
|---|---|
| ["Breast Cancer"] | 13 |
| ["Multiple Sclerosis"] | 10 |
| ["Multiple Myeloma"] | 8 |
| ["Non-Small Cell Lung Cancer"] | 8 |
| ["Diabetic Macular Edema"] | 7 |
| ["Solid Tumors"] | 7 |
| ["Hemophilia A"] | 5 |
| ["Carcinoma, Non-Small-Cell Lung"] | 5 |
Why monitor Roche / Genentech's clinical trial activity
Roche consistently generates the highest volume of new bispecific antibody trial registrations in hematology. Their oncology-neuroscience breadth means new trials span many indication categories — a Roche watchlist captures programs across lymphoma, MS, and ophthalmology simultaneously.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Roche / Genentech's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Roche / Genentech trials
- Sponsor normalization: Roche / Genentech may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Roche / Genentech pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get Started FreeFrequently asked questions
What is Roche/Genentech's focus in clinical trials?
Roche's clinical trial activity is concentrated in oncology (hematologic malignancies, solid tumors), neuroscience (multiple sclerosis, Alzheimer's disease), and ophthalmology. Their bispecific antibody platform generates consistent new trial registrations in B-cell malignancies.
Does DataLookout track both Roche and Genentech trials?
Yes. DataLookout's sponsor normalization maps Genentech and Hoffmann-La Roche to the same canonical entity, so you see the complete combined pipeline regardless of which entity is listed as lead sponsor in ClinicalTrials.gov.
How many Roche/Genentech trials are currently recruiting?
Based on current ClinicalTrials.gov data, 110 Roche/Genentech-sponsored trials are actively recruiting. This includes trials listed under Hoffmann-La Roche, Genentech, and related entities.